344 related articles for article (PubMed ID: 26037152)
21. Expression of erythropoietin messenger ribonucleic acid in wild-type MED12 uterine leiomyomas under estrogenic influence: new insights into related growth disparities.
Asano R; Asai-Sato M; Matsukuma S; Mizushima T; Taguri M; Yoshihara M; Inada M; Fukui A; Suzuki Y; Miyagi Y; Miyagi E
Fertil Steril; 2019 Jan; 111(1):178-185. PubMed ID: 30554729
[TBL] [Abstract][Full Text] [Related]
22. HMGA2 and MED12 alterations frequently co-occur in uterine leiomyomas.
Galindo LJ; Hernández-Beeftink T; Salas A; Jung Y; Reyes R; de Oca FM; Hernández M; Almeida TA
Gynecol Oncol; 2018 Sep; 150(3):562-568. PubMed ID: 30017537
[TBL] [Abstract][Full Text] [Related]
23. Med12 gain-of-function mutation causes leiomyomas and genomic instability.
Mittal P; Shin YH; Yatsenko SA; Castro CA; Surti U; Rajkovic A
J Clin Invest; 2015 Aug; 125(8):3280-4. PubMed ID: 26193636
[TBL] [Abstract][Full Text] [Related]
24. MED12 exon 2 mutations in histopathological uterine leiomyoma variants.
Mäkinen N; Vahteristo P; Kämpjärvi K; Arola J; Bützow R; Aaltonen LA
Eur J Hum Genet; 2013 Nov; 21(11):1300-3. PubMed ID: 23443020
[TBL] [Abstract][Full Text] [Related]
25. Uterine leiomyoma-linked MED12 mutations disrupt mediator-associated CDK activity.
Turunen M; Spaeth JM; Keskitalo S; Park MJ; Kivioja T; Clark AD; Mäkinen N; Gao F; Palin K; Nurkkala H; Vähärautio A; Aavikko M; Kämpjärvi K; Vahteristo P; Kim CA; Aaltonen LA; Varjosalo M; Taipale J; Boyer TG
Cell Rep; 2014 May; 7(3):654-60. PubMed ID: 24746821
[TBL] [Abstract][Full Text] [Related]
26. The study of MED12 gene mutations in uterine leiomyomas from Iranian patients.
Sadeghi S; Khorrami M; Amin-Beidokhti M; Abbasi M; Kamalian Z; Irani S; Omrani M; Azmoodeh O; Mirfakhraie R
Tumour Biol; 2016 Feb; 37(2):1567-71. PubMed ID: 26298726
[TBL] [Abstract][Full Text] [Related]
27. Vitamin D as an effective treatment in human uterine leiomyomas independent of mediator complex subunit 12 mutation.
Corachán A; Trejo MG; Carbajo-García MC; Monleón J; Escrig J; Faus A; Pellicer A; Cervelló I; Ferrero H
Fertil Steril; 2021 Feb; 115(2):512-521. PubMed ID: 33036796
[TBL] [Abstract][Full Text] [Related]
28. MED12 is frequently mutated in ovarian and other adnexal leiomyomas.
Li Z; Maeda D; Kudo-Asabe Y; Tamura D; Nanjo H; Hayashi A; Ikemura M; Fukayama M; Goto A
Hum Pathol; 2018 Nov; 81():89-95. PubMed ID: 29944972
[TBL] [Abstract][Full Text] [Related]
29. Multiple clinical characteristics separate MED12-mutation-positive and -negative uterine leiomyomas.
Heinonen HR; Pasanen A; Heikinheimo O; Tanskanen T; Palin K; Tolvanen J; Vahteristo P; Sjöberg J; Pitkänen E; Bützow R; Mäkinen N; Aaltonen LA
Sci Rep; 2017 Apr; 7(1):1015. PubMed ID: 28432313
[TBL] [Abstract][Full Text] [Related]
30. Detection of MED12 mutations in mesenchymal components of uterine adenomyomas.
Kito M; Maeda D; Kudo-Asabe Y; Tamura D; Makino K; Sageshima M; Nanjo H; Terada Y; Goto A
Hum Pathol; 2021 Mar; 109():31-36. PubMed ID: 33259844
[TBL] [Abstract][Full Text] [Related]
31. MED12 mutations and FH inactivation are mutually exclusive in uterine leiomyomas.
Kämpjärvi K; Mäkinen N; Mehine M; Välipakka S; Uimari O; Pitkänen E; Heinonen HR; Heikkinen T; Tolvanen J; Ahtikoski A; Frizzell N; Sarvilinna N; Sjöberg J; Bützow R; Aaltonen LA; Vahteristo P
Br J Cancer; 2016 Jun; 114(12):1405-11. PubMed ID: 27187686
[TBL] [Abstract][Full Text] [Related]
32. MED12 exon 2 mutations are common in uterine leiomyomas from South African patients.
Mäkinen N; Heinonen HR; Moore S; Tomlinson IP; van der Spuy ZM; Aaltonen LA
Oncotarget; 2011 Dec; 2(12):966-9. PubMed ID: 22182697
[TBL] [Abstract][Full Text] [Related]
33. Mutation analysis of components of the Mediator kinase module in MED12 mutation-negative uterine leiomyomas.
Mäkinen N; Heinonen HR; Sjöberg J; Taipale J; Vahteristo P; Aaltonen LA
Br J Cancer; 2014 Apr; 110(9):2246-9. PubMed ID: 24642626
[TBL] [Abstract][Full Text] [Related]
34. [MED12 gene mutations in women with uterine myoma].
Osinovskaya NS; Ivashchenko TE; Dolinskii AK; Sultanov IY; Ghimbovchi S; Hoffman E; Bezhenar VF; Baranov VS
Genetika; 2013 Dec; 49(12):1426-31. PubMed ID: 25438604
[TBL] [Abstract][Full Text] [Related]
35. Analysis of
Lee M; Cheon K; Chae B; Hwang H; Kim HK; Chung YJ; Song JY; Cho HH; Kim JH; Kim MR
Int J Med Sci; 2018; 15(2):124-128. PubMed ID: 29333096
[TBL] [Abstract][Full Text] [Related]
36. Clonally related uterine leiomyomas are common and display branched tumor evolution.
Mehine M; Heinonen HR; Sarvilinna N; Pitkänen E; Mäkinen N; Katainen R; Tuupanen S; Bützow R; Sjöberg J; Aaltonen LA
Hum Mol Genet; 2015 Aug; 24(15):4407-16. PubMed ID: 25964426
[TBL] [Abstract][Full Text] [Related]
37. MED12 mutations in uterine leiomyomas: prediction of volume reduction by gonadotropin-releasing hormone agonists.
Nagai K; Asano R; Sekiguchi F; Asai-Sato M; Miyagi Y; Miyagi E
Am J Obstet Gynecol; 2023 Feb; 228(2):207.e1-207.e9. PubMed ID: 36150519
[TBL] [Abstract][Full Text] [Related]
38. Exploring chromosomal abnormalities and genetic changes in uterine smooth muscle tumors.
Liegl-Atzwanger B; Heitzer E; Flicker K; Müller S; Ulz P; Saglam O; Tavassoli F; Devouassoux-Shisheboran M; Geigl J; Moinfar F
Mod Pathol; 2016 Oct; 29(10):1262-77. PubMed ID: 27363490
[TBL] [Abstract][Full Text] [Related]
39. A mediator complex subunit 12 gain-of-function mutation induces partial leiomyoma cell properties in human uterine smooth muscle cells.
Takao T; Ono M; Yoshimasa Y; Masuda H; Maruyama T
F S Sci; 2022 Aug; 3(3):288-298. PubMed ID: 35643626
[TBL] [Abstract][Full Text] [Related]
40. Differential DNA Hydroxymethylation in Human Uterine Leiomyoma Cells Depending on the Phase of Menstrual Cycle and Presence of MED12 Gene Mutations.
Kol'tsova AS; Pendina AA; Efimova OA; Kaminskaya AN; Tikhonov AV; Osinovskaya NS; Sultanov IY; Shved NY; Kakhiani MI; Baranov VS
Bull Exp Biol Med; 2017 Sep; 163(5):646-649. PubMed ID: 28944423
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
